Natera, Inc. has announced that it has achieved a significant milestone with over 100 peer-reviewed publications on its Signatera test, which is used for personalized and tumor-informed molecular residual disease (MRD) testing. These studies have been published in prestigious journals, highlighting the test's validation and importance in the field.